Sistema de Salut de Catalunya
Institut Català de la Salut
[Chapman A] Maverex Market Access, Newcastle upon Tyne, UK. [Barouch DH] Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. [Lip GYH] Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Medical University of Bialystok, Bialystok, Poland. [Pliakas T] BioNTech SE, Mainz, Germany. Impact Epilysis, Thessaloniki, Greece. [Polverino E] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. [Sourij H] Trials Unit for Interdisciplinary Metabolic Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
Vall d'Hebron Barcelona Hospital Campus
2025-09-22T08:15:16Z
2025-09-22T08:15:16Z
2025-09
COVID-19; Cardiovascular diseases; Comorbidity
COVID-19; Cardiovascular diseases; Comorbidity
COVID-19; Malalties cardiovasculars; Comorbiditat
Objectives This is the first meta-analysis assessing mortality and hospitalization risk from COVID-19 in individuals with comorbidities versus those without during the Omicron era. Methods A systematic search (Embase, MEDLINE, PubMed, Europe PMC, Latin American and Caribbean Health Sciences Literature, Cochrane COVID-19 Study Register, WHO COVID-19 Database) identified studies published between January 2022 and March 2024. Studies included people with at least one of the following comorbidities: cardiovascular/cerebrovascular disease, chronic lung conditions, diabetes, and obesity. Studies were synthesized quantitatively using random-effect models. Evaluated outcomes were risk of death, hospitalization, intensive care unit (ICU) admission, and any combination of these outcomes. Results Of 72 studies, 68 were meta-analyzed. Participant numbers per comorbidity ranged from 328,870 to 13,720,480. Risks of death, hospitalization, and the combined outcome were increased in individuals with cerebrovascular disease, chronic obstructive pulmonary disease, diabetes, respiratory diseases, heart disease, and heart failure (pooled relative risk [RR] range: 1.27 [heart disease, hospitalization; 95% CI: 1.17-1.38] to 1.78 [heart failure, death: 95% CI: 1.46-2.16]). Diabetes and obesity were associated with increased ICU admission risk (RR: 1.20, 95% CI: 1.04-1.38; RR: 1.32, 95% CI: 1.11-1.57, respectively). Conclusion During the Omicron era, individuals with comorbidities faced increased risks of severe outcomes from COVID-19.
This study was funded by BioNTech SE, Mainz, Germany, which supported the study design; the collection, analysis and interpretation of data; the writing of the report; and the decision to submit the article for publication.
Article
Published version
English
COVID-19 (Malaltia); Comorbiditat; Hospitals - Ingressos i altes; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; HEALTH CARE::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Comorbidity; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Patient Care::Hospitalization; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; ATENCIÓN DE SALUD::calidad, acceso y evaluación de la atención sanitaria::calidad de la atención sanitaria::factores epidemiológicos::comorbilidad; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::asistencia al paciente::hospitalización
Elsevier
International Journal of Infectious Diseases;158
https://doi.org/10.1016/j.ijid.2025.107958
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1655]
